Interés Humano

Rusia prueba su vacuna contra la covid-19 en 40.000 personas

Participantes deben residir en la capital, tener nacionalidad rusa y cobertura médica vigente

(FILES) In this file photo three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19. - The Canadian government announced on August 31, 2020 a deal with American biotech firm Novavax for 76 million doses of its Covid-19 vaccine in development, if it proves to be effective against the new coronavirus. The NVX-CoV2373 vaccine candidate, which is currently in Phase 2 clinical trials to evaluate its safety and immunogenicity, could be delivered in the second quarter of 2021, Ottawa and the company said in a joint statement.
Procurement Minister Anita Anand said the deal "will give Canadians access to a promising COVID-19 vaccine candidate." (Photo by ANDREW CABALLERO-REYNOLDS / AFP)
(FILES) In this file photo three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19. - The Canadian government announced on August 31, 2020 a deal with American biotech firm Novavax for 76 million doses of its Covid-19 vaccine in development, if it proves to be effective against the new coronavirus. The NVX-CoV2373 vaccine candidate, which is currently in Phase 2 clinical trials to evaluate its safety and immunogenicity, could be delivered in the second quarter of 2021, Ottawa and the company said in a joint statement. Procurement Minister Anita Anand said the deal "will give Canadians access to a promising COVID-19 vaccine candidate." (Photo by ANDREW CABALLERO-REYNOLDS / AFP) ANDREW CABALLERO-REYNOLDS
Vacunas Tres posibles vacunas contra el coronavirus en una bandeja en los laboratorios Novavax, en Gaithersburg, Maryland, el 20 de marzo del 2020. Foto: AFP (ANDREW CABALLERO-REYNOLDS/AFP)

Moscú. Las autoridades moscovitas anunciaron este miércoles que comenzaron los ensayos de la vacuna rusa contra la covid-19 con 40.000 habitantes de la capital, la última etapa de las pruebas de la misma, anunciada en agosto con gran pompa.

"Los primeros participantes fueron vacunados en esta jornada en establecimientos médicos de la capital", se congratuló en un comunicado la teniente de alcalde de Moscú, Anastasia Rakova, saludando un "día importante no solamente para la ciudad, sino para todo el país".

‌
‌

‌

‌
‌

‌

‌